E.C. ABBOTT, M.D.; R. MARTIN, M.D.
To the editor: We wish to comment on the paper by McDougall and Greig pertaining to 125I therapy for Graves' disease (1). This group had previously reported on 257 patients (2). Three other groups have also studied a total of 189 patients, with varying follow-up periods (3-5). We recently reported our experience with 125I in 20 cases of Graves' disease and compared the short-term follow-up with that of a similar group given 131I between 1972-75 (6). Twenty patients (10 women) were given 32 treatments with 125I (mean dose, 5.9 mCi; range, 3 to 8 mCi) based only on clinical severity
ABBOTT E, MARTIN R. 125I Therapy. Ann Intern Med. ;87:797. doi: 10.7326/0003-4819-87-6-797_2
Download citation file:
Published: Ann Intern Med. 1977;87(6):797.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use